Adage Capital Partners’s Applied Therapeutics APLT Stock Holding History

Adage Capital Partners’s Portfolio APLT Stock Details APLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,211,629	Closed	-$121K	–	963
2025 Q4	$121K	Sell	1,211,629 -1,000,000	-45%	-$635K	﹤0.01%	892
2025 Q3	$1.34M	Buy	2,211,629 +1,000,000	+83%	+$471K	﹤0.01%	829
2025 Q2	$377K	Sell	1,211,629 -750,000	-38%	-$290K	﹤0.01%	817
2025 Q1	$959K	Hold	1,961,629	–	–	﹤0.01%	797
2024 Q4	$1.68M	Sell	1,961,629 -2,150,732	-52%	-$13.5M	﹤0.01%	797
2024 Q3	$35M	Buy	4,112,361 +1,337,577	+48%	+$7.88M	0.06%	300
2024 Q2	$13M	Buy	2,774,784 +125,000	+5%	+$592K	0.02%	551
2024 Q1	$18M	Buy	+2,649,784	New	+$11.9M	0.03%	480

Adage Capital Partners's APLT Position: Q1 2026 in Review

Adage Capital Partners sold out of Applied Therapeutics (APLT) in Q1 2026, closing a stake of 1,211,629 shares — an estimated $121K sold.

Adage Capital Partners first reported a position in APLT in Q1 2024 and held it in 8 quarters. The position peaked at $35M in Q3 2024. 0 funds tracked by Wall St. Rank hold APLT as of Q1 2026.

Adage Capital Partners reported no remaining Applied Therapeutics position as of Q1 2026 after selling out during the quarter.
Adage Capital Partners sold 1,211,629 Applied Therapeutics shares in Q1 2026, an estimated $121K.
Adage Capital Partners first reported a position in Applied Therapeutics in Q1 2024 and held it in 8 quarters.
Adage Capital Partners's Applied Therapeutics position peaked at $35M in Q3 2024.
0 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.